COMPASS Pathways plc (CMPS) News
Follow COMPASS Pathways plc (CMPS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 47 public stories across 26 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
RBC Says Compass Pathways Remains on Track for COMP360 Launch
Compass Pathways reported third-quarter results; RBC said the company remains on track for the COMP360 launch.
EQUITY | Nov 04, 2026, 05:08 PM UTC
M
CMPS Reports Fiscal Q3 Shareholder Profit of -1.724亿美元
CMPS reported fiscal third-quarter profit attributable to shareholders of -1.724亿美元, up 11.11% year over year, and basic EPS of -1.35美元.
EQUITY | Nov 04, 2026, 06:27 AM UTC
M
Compass Pathways Reports Quarterly Results for September 30 Quarter
EQUITY | Nov 03, 2026, 02:32 PM UTC
M
Compass Pathways Reports Narrower Q3 Net Loss
Compass Pathways reported a narrower net loss in the third quarter.
EQUITY | Nov 03, 2026, 02:05 PM UTC
M
Compass Pathways Reports 2026 Net Loss of $9.83 Million
Compass Pathways reported comprehensive losses of $10.01 million and diluted loss per share of $0.31. Its net loss was $9.83 million, compared with $137.72 million in 2025.
EARNINGS | Nov 03, 2026, 01:32 PM UTC
L
Compass Pathways Expects to Complete COMP360 FDA Filing Within Two Weeks
Compass Pathways expects to complete its New Drug Application for its depression treatment within two weeks. CEO Nath sees a potential commercial launch in the first half of 2027.
EQUITY | Nov 03, 2026, 01:00 PM UTC
M
Compass Pathways cuts Q3 2026 net loss 93%
EQUITY | Nov 03, 2026, 11:58 AM UTC
M
Compass Pathways Reports Q3 Loss of $0.31 per Share
Compass Pathways posted a Q3 loss of $0.31 per share, versus a FactSet estimate of a $0.39 loss.
EQUITY | Nov 03, 2026, 11:47 AM UTC
M
Compass Pathways Reports Q3 EPS
EARNINGS | Nov 03, 2026, 11:43 AM UTC
M
Compass Pathways Reports Q3 Operating Income
Compass Pathways reported Q3 operating income below the IBES estimate.
EARNINGS | Nov 03, 2026, 11:32 AM UTC
L
COMPASS Pathways reports Q3 EPS of USD -0.07
COMPASS Pathways reported Q3 pretax profit of USD -10.937 million.
EARNINGS | Nov 03, 2026, 11:32 AM UTC
M
Compass Pathways Announces Third-Quarter 2026 Results and Business Highlights
The company says its final NDA submission is nearing completion and will be filed in the next two weeks.
EQUITY | Nov 03, 2026, 11:31 AM UTC
M
Compass Pathways Shares Fall 28% on Psychedelic Competition Fears
Compass Pathways shares fell 28% Monday after Usona Institute reportedly completed its FDA application for a psilocybin treatment for major depressive disorder.
EQUITY | Nov 02, 2026, 07:57 PM UTC
M
Compass Pathways to Report Third-Quarter 2026 Results on Nov. 3
Compass Pathways says it will announce its third-quarter 2026 financial results on November 3, 2026.
EQUITY | Oct 27, 2026, 10:30 AM UTC
H
Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript
Compass Pathways (NASDAQ: CMPS ) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and
LIVE | Oct 08, 2026, 07:23 AM UTC
L
Compass Pathways Boucher's Appointment Effective Sept. 30 >CMPS
Compass Pathways Boucher's Appointment Effective Sept. 30 >CMPS
NEWS | Sep 30, 2026, 10:31 AM UTC
L
Compass Pathways plc (CMPS) Names Chief People Officer
Compass Pathways plc appointed Kelley Boucher as Chief People Officer, effective immediately, to support its planned evolution toward a potential COMP360 psilocybin launch, subject to FDA approval targeted for H1 2027.Ma
REGULATION | Sep 30, 2026, 10:30 AM UTC
L
Compass Pathways Appoints Kelley Boucher as Chief People Officer >CMPS
Compass Pathways Appoints Kelley Boucher as Chief People Officer >CMPS
NEWS | Sep 30, 2026, 10:30 AM UTC
L
Compass Pathways Appoints Kelley Boucher as Chief People Officer
Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effecti
NEWS | Sep 30, 2026, 10:30 AM UTC
L
Weekly Recap: FDA seeks data on CMPS NDA and COMP360 52—week results
COMPASS Pathways Plc Sponsored ADR (NASDAQ:CMPS) said its rolling NDA for COMP360 faces FDA requests for more information and an uncertain 60—day acceptance timeline, even as Part C data show repeat doses delivered rapid
REGULATION | Sep 28, 2026, 11:05 AM UTC
L
Key facts: CMPS Phase III ~4—pt MADRS gain; dosing, SPRAVATO sites
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
NEWS | Sep 23, 2026, 07:15 AM UTC
L
As Trump backs psychedelics research, FDA weighs safety and access standards
By Nancy LapidThe U.S. FDA heard calls for clear safety and access standards for psychedelic therapies at a public meeting, the latest step in the Trump administration's push to speed development of treatments such as ib
REGULATION | Sep 15, 2026, 03:16 PM UTC
H
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP diseas
GEOPOLITICS | Sep 15, 2026, 10:30 AM UTC
L
FDA holds public hearing on psychedelic drugs as Trump-driven push gathers pace
By Puyaan Singh and Kamal ChoudhuryThe U.S. FDA is holding a public hearing on Monday to gather feedback on the potential therapeutic use of psychedelic drugs, the latest step in a months-long push by President Donald Tr
REGULATION | Sep 14, 2026, 07:30 PM UTC
L
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDANEW YORK, Sept. 10, 2026 // -- Fluence, a leading provider of professional education in ps
EQUITY | Sep 10, 2026, 12:01 PM UTC
L
Compass Pathways names U.S. grant recipients for COMP360 provider training
Compass Pathways plc said it announced the U.S. grant program recipients to create training programs for healthcare providers involved in delivering post-approval COMP360.
EQUITY | Sep 10, 2026, 10:35 AM UTC
L
Compass Pathways to Participate in Investor Conferences the Week of September 14th
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor
EQUITY | Sep 10, 2026, 10:30 AM UTC
M
CMPS rises after Compass says COMP360 benefits lasted up to a year
Compass Pathways said its experimental COMP360 psilocybin treatment continued to show benefits for some patients with treatment-resistant depression for up to a year.
EQUITY | Sep 09, 2026, 02:06 PM UTC
M
Compass Pathways shares rise ahead of FDA psilocybin hearing
Compass Pathways shares rose Tuesday as investors treated a new commercial-readiness push as a sign the company is preparing to file its psilocybin depression treatment with the FDA. Shares closed up 5% and edged up a fu
REGULATION | Sep 08, 2026, 10:28 PM UTC
L
Compass Pathways to participate in Psych Congress 2026 in New Orleans
Compass Pathways plc (Nasdaq: CMPS) said it will participate in Psych Congress 2026 in New Orleans, LA, from September 14-19.
GEOPOLITICS | Sep 08, 2026, 10:30 AM UTC
M
Compass Pathways advances U.S. rollout plans, hires incentives reported
Compass Pathways said it is advancing a potential U.S. rollout of its COMP360 psilocybin TRD and PTSD programs, with a rolling NDA targeted for H1 2027. It also granted equity to 31 new hires.
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
Compass Pathways grants equity inducement awards to newly hired non-executives
Compass Pathways plc announced it granted equity awards under the company’s 2026 Inducement Plan to thirty-one newly hired non-executive employees, under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 03, 2026, 08:30 PM UTC
L
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fier
EQUITY | Sep 02, 2026, 10:30 AM UTC
L
Compass Pathways to participate in Cantor Global Healthcare conference Sept. 9, 2026
Compass Pathways plc (Nasdaq: CMPS) said management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and participate in a fireside chat at 3…
EQUITY | Sep 01, 2026, 10:30 AM UTC
H
Compass Pathways Collaborates With U.S. Department Of Veterans Affairs On A Multi-Site Randomized Controlled Clinical Trial
The study will evaluate the safety and efficacy of COMP360 psilocybin in the treatment of treatment-resistant depression (TRD) in veterans, including those with concurrent post-traumatic stress disorder (PTSD). The trial
REGULATION | Aug 06, 2026, 10:34 AM UTC
L
CMPS Initiated Equal Weight W/$13.00 PT at Wells Fargo
CMPS Initiated Equal Weight W/$13.00 PT at Wells Fargo
EQUITY | Jul 27, 2026, 12:07 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
CMPS also +9% premarket after ATAI M&A headlines
CMPS also +9% premarket after ATAI M&A headlines
MNA | Jul 16, 2026, 11:28 AM UTC
L
CMPS Compass Pathways announces publication of post-hoc analysis demonstrating distinction of comp360 trial monitoring & support from psycho
CMPS Compass Pathways announces publication of post-hoc analysis demonstrating distinction of comp360 trial monitoring & support from psychotherapy
EQUITY | Jul 16, 2026, 10:35 AM UTC
H
FDA announces availability of final guidance for psychedelic drug research
The agency said,...
EARNINGS | Jul 15, 2026, 03:12 PM UTC
L
DFTX CMPS US health, veterans departments announce mou on psychedelics
DFTX CMPS US health, veterans departments announce mou on psychedelics
EQUITY | Jul 13, 2026, 07:39 PM UTC
H
Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors
Jefferies notes that on...
EQUITY | Jul 13, 2026, 05:12 PM UTC
L
Psychedelic: Compass Pathways reports six-month data for psilocybin drug
In this week's "Psychedelic," recurring series focused on psychedelic stock news, looks back on study results, drug delivery evaluation and last patient dosing. COMPASS PATHWAYS REPORTS SIX-MONTH DATA FROM COMP006 TRIAL:
EQUITY | Jul 09, 2026, 01:49 PM UTC
L
Compass Pathways' COMP360 Data Supports FDA Approval Potential, RBC Says
() -- Compass Pathways' (CMPS) recent six-month trial data for COMP360 in treatment-resistant depression supports its potential for US Food and Drug Administration approval, a 2027 launch, and a more than $1.7 billion ma
REGULATION | Jul 08, 2026, 03:36 PM UTC
L
Compass Pathways announces six-month data from COMP006 trial
Compass Pathways announced the 26-week results from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression which confirm COMP360's rapi
EQUITY | Jul 07, 2026, 07:43 PM UTC
L
Compass Pathways data strengthens launch prospects, says Oppenheimer
Oppenheimer maintains an Outperform rating and $20 price target on shares of Compass Pathways, telling investors in a research note that the Phase 3 COMP006 26-week data reinforce the durable efficacy of COMP360 for trea
EQUITY | Jul 07, 2026, 03:40 PM UTC
H
CMPS: Depression Drug 86% Through Phase 3
CMPS' breakthrough-designated depression drug is 86% through its Phase 3 with topline data due this year
EQUITY | Jun 26, 2026, 01:31 PM UTC